Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Jul;23(7):849-851.
doi: 10.1634/theoncologist.2017-0531. Epub 2018 Apr 17.

Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy

Affiliations
Case Reports

Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy

Sagun Parakh et al. Oncologist. 2018 Jul.

Abstract

Treatment with anti-programmed cell death protein 1 (PD-1) antibodies has demonstrated clinical efficacy in a whole range of malignancies including advanced melanoma, renal cell cancer, bladder cancer, and non-small cell lung cancer. Immune-related adverse events are a unique side effect of checkpoint regulator therapy including anti-PD-1 antibodies. Treatment-related autoimmunity can occur in any organ system, with the median onset usually within 5-15 weeks from the commencement of therapy, depending on the organ system involved. This study describes for the first time a case of delayed autoimmunity occurring 8 months after discontinuing treatment with the anti-PD-1 antibody nivolumab in a patient with metastatic melanoma. The case highlights the need for ongoing surveillance of patients treated with immune checkpoint inhibitors even after cessation of therapy, especially as patients increasingly stop treatment after achieving durable responses.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Figures

Figure 1.
Figure 1.
Positron emission tomography‐computed tomography images. (A): Sites of metastatic disease prior to commencing nivolumab. (B): Four months after commencement of nivolumab, a complete response was seen in all sites of disease apart from a solitary progression of a left adrenal gland metastasis. (C): The patient maintained a complete response after completion of radiotherapy to the left adrenal gland.
Figure 2.
Figure 2.
Time course of liver function tests. Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ‐glutamyltransferase.

References

    1. Callahan MK, Postow MA, Wolchok JD. Targeting T cell co‐receptors for cancer therapy. Immunity 2016;44:1069–1078. - PubMed
    1. Naidoo J, Page DB, Li BT et al. Toxicities of the anti‐PD‐1 and anti‐PD‐L1 immune checkpoint antibodies. Ann Oncol 2015;26:2375–2391. - PMC - PubMed
    1. Weber JS, Hodi FS, Wolchok JD et al. Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol 2016;35:785–792. - PubMed
    1. Larkin J, Chiarion‐Sileni V, Gonzalez R et al., eds. Overall survival results from a phase III trial of nivolumab combined with ipilimumab in treatment‐naïve patients with advanced melanoma (CheckMate 067). Proceedings from the American Association for Cancer Research Annual Meeting; April 1–5, 2017; Washington, DC.
    1. Schachter J, Ribas A, Long GV et al. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open‐label phase 3 study (KEYNOTE‐006). Lancet 2017;390:1853–1862. - PubMed

Publication types

MeSH terms

Substances